Clinical Trial Update: Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Repertaxin to prevent primary graft dysfunction after lung transplantation has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemia-reperfusion Injury
• Lung Transplantation

Drugs mentioned

• Repertaxin (Repertaxin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Ischemia-Reperfusion Injury, Lung Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2024-12-11